Research and Development

With the result of the Brexit referendum, the future of the EMA’s London headquarters was cast in doubt. Now, 19 …

Novartis posted strong results for its wet age-related macular degeneration (AMD) drug, by showing superiority against Eylea in Phase 3 …

A recent report by the OECD shares concerns that the UK’s overall health looks set to face a crisis due …

Friday again, and we bring you the most read articles on our site this week – one of which was …

New findings from the Early Breast Cancer Trialists’ Collaborative Group have demonstrated that oestrogen receptor-positive (ER-positive) breast cancer is able …

Sage Therapeutics share price soared 50% on the release that its two Phase 3 trials of brexanolone showed statistically significant …

Interim report January – September 2017 July – September 2017    

Recipharm today announces that it will initiate a process with the intention of discontinuing manufacturing operations at its facilities in …

A young child has been brought back from the verge of death after an experimental combination of stem cell and …

At least 17,000 people in the UK are living with Stage 4 cancer and have survived for two years or …

In our latest free to attend webinar, we have joined up with NDA to bring you the latest market access …

It is easy to forget the very real dangers that CAR-T treatment present to patients after Novartis and Gilead both …

Research, published in the Journal of Women’s Health, that aimed to determine the effects of the FDA’s guidance on the …

Novartis has revealed that its immunotherapy drug Kisqali (ribociclib) met its primary endpoint of progression-free survival in its second Phase …

Dear Colleague,